Viridian Therapeutics Positioned for Growth in TED Market Amidst Competitive Setbacks
I'm PortAI, I can summarize articles.
Gregory Renza from Truist Financial maintains a Buy rating on Viridian Therapeutics with a $41 target, citing competitive setbacks in the TED market. Argenx's halted studies for Vyvgart Hytrulo open opportunities for Viridian's Veli’ and VRDN-003 SC programs. Renza forecasts a mid-2026 launch for Veli’ with $700M peak revenue and a 2027 launch for VRDN-003 SC with $730M potential. The IGF-1Ra mechanism is seen as promising for TED treatment. Wedbush also maintains a Buy rating with a $47 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments